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Background: Chronic Obstructive Pulmonary Disease (COPD) is characterized by an enhanced inflammatory
response to smoking that persists despite quitting. The resolution of inflammation (catabasis) is a complex and
highly regulated process where tissue resident macrophages play a key role since they phagocytose apoptotic cells
(efferocytosis), preventing their secondary necrosis and the spill-over of their pro-inflammatory cytoplasmic content,
and release pro-resolution and tissue repair molecules, such as TGFβ, VEGF and HGF. Because inflammation does
not resolve in COPD, we hypothesized that catabasis may be abnormal in these patients.
Methods: To explore this hypothesis, we studied lung tissue samples obtained at surgery from 21 COPD patients,
22 smokers with normal spirometry and 13 non-smokers controls. In these samples we used: (1)
immunohistochemistry to assess the expression of CD44, CD36, VEGF and TGFβ in lung macrophages; (2) real time
PCR to determine HGF, PPARγ, TGFβ, VEGF and MMP-9 gene expression; and, (3) ELISA to quantify lipoxin A4, a lipid
mediator of catabasis.
Results: We found that current and former smokers with COPD showed: (1) more inflammation (higher MMP-9
expression); (2) reduced macrophage surface expression of CD44, a key efferocytosis receptor; and, (3) similar levels
of TGFβ, VEGF, HGF, PPARγ, and lipoxin A4 than smokers with normal spirometry, despite the presence of
inflammation and disease.
Conclusions: These results identify several potential abnormalities of catabasis in patients with COPD.
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Chronic obstructive pulmonary disease (COPD) is char-
acterized by an excessive inflammatory response to
inhaled particles and gases, particularly tobacco smoking
[1]. Recent studies have shown that this enhanced re-
sponse persists after quitting smoking [2,3]. The
mechanisms explaining this observation are unknown
but unremitting inflammation is likely to contribute to
the progression of the disease and may limit the re-
sponse to anti-inflammatory therapy.* Correspondence: alvar.agusti@clinic.ub.es
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reproduction in any medium, provided the orThe resolution of inflammation (so-called, “catabasis”)
is not a passive process that simply occurs when the
stimuli that generated it (i.e., smoking) disappears [4,5].
On the contrary, it is a highly regulated process [4,5]
that requires the coordinated action of specific lipid
mediators (lipoxins, protectins and resolvins), pro-
resolution and repair proteins (such as tissue growth fac-
tor beta (TGF-β), vascular endothelial growth factor
(VEGF), and hepatocyte growth factor (HGF)), anti-
inflammatory nuclear receptors (such as peroxisome
proliferator-activated receptors (PPAR)) and the elimin-
ation of apoptotic cells (mostly neutrophils and epithelial
cells) by macrophages, a process known as “efferocyto-
sis” [4-6]. Efferocytosis prevents secondary necrosis of
apoptotic cells (thus, the liberation of their pro-
inflammatory cytoplasmic content) and stimulates the
active release by macrophages of TGF-β, VEGF andal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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receptors involved in efferocytosis [7,8].
Since inflammation persists in COPD patients despite
quitting smoking [2,3], we hypothesized that catabasis
might be abnormal in these patients. To explore this hy-
pothesis, we compared the markers of catabasis dis-
cussed above in lung tissue samples obtained from
COPD patients, smokers with normal spirometry and
never smoker controls.
Methods
Study design and ethics
This is a prospective, descriptive and controlled study.
Lung tissue samples were collected, processed and pro-
vided by the Lung Tissue Biobank of CIBERES (www.
ciberes.org), as described elsewhere [9]. They were
obtained from volunteers that required lung resectional
surgery because of clinical reasons, mostly lung cancer.
All participants signed their consent to donate these
samples for research purposes, and the Ethics Commit-
tee of the CIBERES bio-bank approved their use for the
current project.
Study subjects
The diagnosis of COPD was established according to the
GOLD recommendations [1]. Exclusion criteria included
the presence of diffuse pulmonary inflammation or fibro-
sis, the absence of tumour-free lung tissue specimens, ob-
struction of central bronchi due to the tumour and/or
previous treatment with chemotherapy or radiotherapy.
Patients with other chronic inflammatory diseases, alco-
holism or receiving systemic anti-inflammatory therapies
were also excluded. No patient had an upper respiratory
tract infection and/or receive antibiotics perioperatively.
Lung function
Forced spirometry was obtained in all participants
according to international guidelines [10]. Reference
values were those of a Mediterranean population [11].
Pulmonary tissue sampling and processing
Lung tissue samples were always obtained from non-
affected distant areas from the tumour. These samples
were either: (1) frozen rapidly in liquid nitrogen, cut into
0.3×0.3×0.3 slices and stored at – 80°C until analysis; or
(2) fixed in formalin for immunohistochemistry analysis,
as detailed below.
Immunohistochemistry
Formalin-fixed paraffin-embebbed tissue sections (3 μm
thick) were immunostained with the following monoclo-
nal mouse antibodies: anti-human CD44, Phagocytic
Glycoprotein-1, clone DF1485 (Dako, Glostrup, Den-
mark); anti-human VEGF, clone VG1 (Dako, Glostrup,Denmark); anti-human TGFbeta (AbDSerotec, Oxford,
UK); anti-human CD36, clone SMO, (AbDSerotec, Ox-
ford, UK). The optimal dilutions for all antibodies were
identified by examining the intensity of staining obtained
with a series of dilutions, which produced specific and
easily visible signals on paraffin sections made from the
same control tissue before performing the staining
protocol on all sections. Positive controls consisted of
human tonsil tissue (CD44, VEGF), human breast car-
cinoma (TGFβ), and human heart tissue (CD36). Nega-
tive controls consisted of omission of the primary
antibody. Sections were deparaffinized, rehydrated, and
subjected to an antigen retrieval step. Endogenous per-
oxidase was inactivated with 0.3% hydrogen peroxide,
before incubation with specific monoclonal antibodies
against CD44 (1:50 dilution), CD36 (1:10), VEGF (1:50),
TGFβ (1:325). LSAB + System – HRP (Dako, Glostrup,
Denmark) was utilized as detection kit, and 3’- diamino-
benzadine (Dako) as the chromogen. Expression of
CD44, CD36, VEGF and TGFβ in five hundred macro-
phages was assessed in a semiquantitative analysis using
a visual analogue scale. Macrophages were identified by
their morphologic characteristics following previous
published methodology [12,13] (Figure 1). The staining
intensity was graded and expressed as: 0= absence of
staining (no staining at all), 1= moderate staining (both
cell membrane and cytoplasma showing mild brown
staining), 2= intense staining (cell membrane showing
intense, dark brown staining with or without similar
cytoplasmic staining). Samples were analyzed by two ex-
pert and independent observers (AN, CG), mean values
were used for analysis, and results were expressed as
percentage of macrophages with intense staining.
Gene expression
Total lung RNA was obtained from frozen tissue samples
with the RNAqueous kit. RNA concentration was assessed
in a Nano Drop-1000 spectrophotometer (Nano Drop
Technologies Wilmington, DE) and its integrity was tested
on a 6000 LabChip in a 2100 Bioanalyzer (Agilent Tech-
nologies, Palo Alto, CA). cDNA synthesis from 1 μg of
total RNA was performed using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster
City, CA) in a MJ Research PTC-100 thermal cycler (Bio-
Rad, Hercules, CA). Validated and predesigned TaqMan
Gene Expression Assays (Applied Biosystems) were used
to quantify hepatocyte growth factor (HGF) (ID:
Hs00300159_m1), peroxisome proliferator-activated re-
ceptor (PPAR) γ (ID: 01115513_m1), transforming growth
factor (TGF) β1 (ID: Hs00171257_m1) vascular endothe-
lial growth factor (VEGF) A (ID: Hs00173626_m1) and
MMP-9 (ID: Hs00234579_m1) gene expression using β-
actin (ID: Hs99999903_m1) as an endogenous control.
Briefly, PCR reactions were performed in duplicate using
Absent/moderate staining Intense staining
CD44 
CD36 
VEGF
TGFβ
Figure 1 Representative examples of different macrophage immunostaining intensities (absent/moderate vs. intense staining) for
CD44, CD36, VEGF and TGFβ. For further explanations, see text.
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20 μl containing 1.25 μl cDNA. Quantitative real-time
PCR amplifications were performed in an ABI Prism
7900HT Real Time PCR System (Applied Biosytems). Real
time PCR results were analyzed with the Sequence De-
tector Software version 2.1 (Applied Biosystems). Relative
quantification of gene expression was performed using the
comparative Ct method. The amount of target gene, nor-
malized to β-actin and relative to a calibrator, was deter-
mined by the arithmetic equation 2-ΔCt described in the
comparative Ct method (User Bulletin #2; http://docs.
appliedbiosystems.com/pebiodocs/04303859.pdf).
Lipoxin A4
Frozen lung tissue samples (120 mg) were homogenized
in cold DPBS++ with an Ultra-Turrax T 25 Basic
homogenizer (IKA-Werke, Staufen, Germany). Two
volumes of cold methanol were added to the homoge-
nates and incubated 30 minutes on ice. Homogenates
were centrifuged at 2000 rpm for 15 minutes at 4°C and
supernatants were collected. Pellets were re-suspended
in 1 ml of ethanol and centrifuged again at 2000 rpm for15 minutes at 4°C. Supernatants were combined and
brought to a final volume of 10 ml with distilled water.
Samples were acidified to pH 3.5, transferred into syr-
inges and loaded onto activated C18-silica reverse-phase
cartridges. The eluted methyl formate fraction was rap-
idly evaporated under a stream of nitrogen, resuspended
in 1 ml of methanol and kept at −80°C until analysis of
LXA4 by ELISA (Neogen Corporation, Lansing, MI).
Statistical analysis
Results are presented as mean ± standard deviation, and
percentages, as indicated. To compare differences between
groups we used nonparametric statistics (Kruskal-Wallis
test followed by Mann–Whitney U-test if appropriate).
Correlations between variables of interest were explored
using the Spearman correlation test. A p value lower than
0.05 (two-tailed) was considered significant.
Results
Characterization of participants
Table 1 presents the main demographic, clinical and
functional characteristics of participants. Age was similar
Table 1 Clinical and lung function data (mean±SD) of all participants
COPD patients Smokers with normal spirometry Non
smokers
Overall
p valueCurrent smokers Former smokers Current smokers Former smokers
N 10 11 11 11 13
Age, years 64 ± 9 69 ± 10* 55 ± 8+ 66 ± 10 62 ± 9 <0.01
Males, n (%) 10 (100) 10 (91) 8 (73) 9 (82) 3 (23) <0.0001
Smoking exposure, pack-yr. 64 ± 41 58 ± 22 47 ± 26 64 ± 13 _ NS
FEV1 / FVC1, % 56 ± 12
& 54 ± 7& 77 ± 7 77 ± 6 83 ± 4 <0.0001
FEV1, % reference 70 ± 12
& 67 ± 11& 97 ± 14 96 ± 19 98 ± 11 <0.0001
NS: non-significant. * p <0.01 vs. current smokers; + p < 0.05 vs. former smokers; & p<0.001 vs. current smokers, former smokers and never smokers.
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spirometry were slightly younger. Most participants were
males, except for never smokers where females predom-
inate. Cumulative smoking exposure was similar be-
tween all smoker groups. All former smokers quit
smoking more than 5 years before tissue sampling. As
expected, spirometry was abnormal in patients with
COPD and within the normal range in the other two
groups. Four COPD patients had GOLD grade I and 17
GOLD grade II airflow limitation.
Immunohistochemistry
The pattern of macrophage immunostaining was pre-
dominantly membranous for anti-CD44 and anti-CD360
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Figure 2 Individual and mean (bars) values of the proportion of macr
in patients with COPD, smokers with normal spirometry and non-smo
NS = non-smokers). For further explanations, see text.antibodies, whereas it was predominantly cytoplasmic
for anti-VEGF and anti-TGFβ (Figure 1), as expected be-
cause of their respective cellular localization. Figure 2
presents the individual and mean (bars) values of the
proportion of macrophages with intense immunostain-
ing for CD44, CD36, VEGF and TGFβ in all participants.
Independently of their smoking status (current vs.
former), CD44 expression was lower in patients with
COPD than in smokers and ex-smokers with normal
spirometry and non-smokers (p<0.0001); by contrast,
macrophage immunostaining of CD36, VEGF and TGFβ
was similar in all groups (Figure 2). CD44 expression
was not related to airflow limitation or treatment with
inhaled steroids.0
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Figure 3 presents the individual and mean (bars) values
of HGF, PPARγ, TGFβ and VEGF expression in lung tis-
sue samples. We did not observe significant differences
between groups for any of these markers. Figure 3 also
shows that the lung expression of MMP-9, a marker of
tissue inflammation was, as expected, significantly higher
in patients with COPD, both current and former smo-
kers, than in controls. Additional file 1: Table S1 (on-line
supplement) presents a correlation matrix between HGF,
PPARγ, TGFβ, VEGF and MMP-9 expression in lung tis-
sue, and the percentage of macrophages with intense
staining of CD36, VEGF, TGFβ, and CD44, as well as
FEV1 values in COPD patients. The same information is
presented graphically (heat-map) in Figure 4 whereas
Additional file 1: Table S2 (on-line supplement) presents
the individual Z-scores en each patient for each inflam-
matory marker determined in pulmonary macrophages
(M) and lung tissue extracts. It is of note that lung tissue
markers (Figure 4, bottom right corner of the heat-map)
were much better correlated among them than with
macrophage markers, which were not particularly well
correlated either among themselves (Figure 4, top left
corner of the heat-map; see also Additional file 1: Table
S1 on-line supplement).
Pulmonary concentration of Lipoxin A4
The concentration of lipoxin A4 in lung tissue homoge-
nates was similar in all groups studied (Figure 5).HGF
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
R
Q
R
Q
S       EX-S     S      EX-S    NS S       EX-S    
S       EX-S     S      EX-S     NS
COPD Smokers COPD
COPD Smokers
VEGF
0
1
2
3
4
5
6
7
PP
0
1
2
3
4
5
6
7
Figure 3 Individual and mean (bars) values of HGF, PPARγ, TGFβ, VEG
patients with COPD, smokers with normal spirometry and non-smoke
** p < 0.01. For further explanations, see text.Discussion
Main results show that, compared with controls, COPD
patients present: (1) reduced surface expression of
CD44, a key macrophage efferocytosis receptor; and,
(2) similar lung tissue levels of TGFβ, VEGF, and HGF,
despite the presence of more inflammation and tissue
damage.
Previous studies
Hodge et al. reported that the ability of alveolar macro-
phages to ingest apoptotic bronchial epithelial cells and
neutrophils (efferocytosis) was reduced in COPD
[14,15]. We did not studied efferocytosis directly, but we
found a marked reduction in the surface expression of
CD44 in pulmonary macrophages (Figure 2), as other
authors and our own group have previously reported in
broncho-alveolar lavage fluid macrophages [14,16] . This
was not the case for CD36, also in keeping with previous
results [17]. Likewise, we did not find significant differ-
ences in HGF, VEGF, TGFβ or PPARγ expression in the
lungs of COPD and controls (Figure 3) as others showed
before [18-20]. Finally, several lipid molecules, such as
lipoxins, protectins and resolvins, are also important
mediators of catabasis. Lipoxins reduce neutrophil re-
cruitment and stimulate efferocytosis [21], whereas pro-
tectins and resolvins interact with lipoxins to enhance
catabasis [22]. Reduced levels of lipoxin A [23,24] and
protectin D1 [25] have been reported in patients with se-
vere asthma [26]. In COPD, results are not consistentMMP-9
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Figure 5 Individual and mean (bars) values of lipoxin A4 (LXA4) concentration in lung tissue homogenates in patients with COPD, smokers
with normal spirometry and non-smokers (S = smokers; EX-S = ex-smokers; NS = non-smokers). For further explanations, see text.
Figure 4 Spearman correlations heat map. Colours in each cell indicate the strength of the relationship, from white (no relationship) to dark
red (strong relationship). The exact Rho correlation coefficient and corresponding p values are presented in Additional file 1: Table S1 (on-line
supplement). For further explanations, see text.
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Vachier et al. found moderately increased levels of
lipoxin A4 in sputum of COPD patients [27] whereas
Fritscher et al. reported reduced concentrations in
exhaled breath condensate of these patients [28]. On the
other hand, in peripheral blood, Bozinovski et al. showed
that serum amyloid A (SAA) increased disproportion-
ately relative to LXA4 during acute exacerbation of the
disease [29]. SAA is a hepatic acute-phase protein that
can interact with Lipoxin A4 receptors (ALX/FPR2) and,
at variance to Lipoxin A4, stimulate neutrophil recruit-
ment and activation [29]. Interestingly, ALX/FPR2 is also
important in the process of apoptotic cell clearance
(efferocytosis) [30], a key component of catabasis [4-6].
In our study, in lung tissue homogenates, we did not
find significant differences in the concentration of
Lipoxin A4 among the five groups of subjects studied
here (Figure 5).
Interpretation of findings
A key observation of our study is that patients with
COPD show a reduced surface expression of CD44 in
lung macrophages (Figure 2). CD44 plays a pivotal role
in efferocytosis and, hence, in the regulation of catabasis
[8,31]. This is clearly illustrated in CD44 knock-out mice
which, following lung injury, succumb to unremitting
inflammation characterized by impaired clearance of
apoptotic neutrophils and defective TGFβ release, a
phenotype that could be reversed partially by reconsti-
tution with CD44+ cells [31]. Hence, the reduced sur-
face expression of CD44 in lung macrophages of COPD
observed in our study (Figure 2) has the potential to
favour secondary necrosis of apoptotic cells (known to be
increased in COPD [32,33]) and to prevent an adequate
pro-resolution response (enhanced TGFβ, VEGF, and
HGF macrophage release). We propose that the absence
of significant differences between COPD patients and
controls in either protein (Figure 3) or lipid (Figure 4)
mediators of catabasis actually supports a blunted cata-
batic response in COPD because the presence of chronic
inflammation and lung tissue damage should enhance it
[34]. We accept that this is a hypothesis that will have
to be confirmed or refuted in future studies but, in
keeping with this proposal, our group previously showed
that alveolar macrophages of COPD patients release less
TGFβ than controls when stimulated in vitro with LPS
[35]. This also suggests a defective response to a well-
characterized pro-inflammatory stimulus. We hypothe-
sized that all these mechanisms can contribute to the
enhanced and persistent inflammation (higher MMP-9)
that characterizes COPD and to defective tissue repair.
Further, a self-sustained loop can develop because
MMP-9 is known to participate in the shedding of
CD44 [36], although we did not find a significantrelationship between MMP-9 expression and % CD44
positive macrophages in our patients (Figure 4,
Additional file 1: Table S1 on-line supplement), and
the absence of VEGF stimulation causes lung cell
apoptosis [37]. The iteration of this loop can contrib-
ute, in combination with the absence of a significant
up-regulation of PPARγ or lipoxin A4, to the presence of
unremitting inflammation in COPD and disease progres-
sion, even after quitting smoking. These potential
mechanisms deserve further research.
Not all smokers develop COPD. Our results show that
CD44 surface expression in macrophage is only reduced
in those with COPD. Why is this the case cannot be
answered from our study and also requires further re-
search. However, potential mechanisms may include one
or more of the following, among others. Susceptible
smokers with COPD are likely to have a genetic back-
ground that favours an enhanced inflammatory response
[38], and this may initiate the process by shedding
macrophage CD44 [36], hence limiting the efficiency of
efferocytosis [7,8]. Alternatively, there may be individual
differences in the expression of CD44 [39], making smo-
kers with low constitutive CD44 expression more sus-
ceptible to the development of COPD since, as discussed
above, CD44-deficient mice succumb to unremitting in-
flammation after lung injury with impaired clearance of
apoptotic neutrophils and impaired activation of TGFβ
[31]. It is also possible that efferocytosis of apoptotic
cells may be overloaded (hence secondary necrosis
allowed) if the number of apoptotic cells increases sig-
nificantly, as it seems to be the case in COPD [32,33].
And, of course, none of these mechanisms is mutually
exclusive, so a combination of them may also occur.
Strengths and limitations
The fact that we studied lung tissue macrophages is at
variance with previous studies investigating broncho-
alveolar lavage samples and is a clear strength of our
study. However, we acknowledge that our study has lim-
itations that deserve comment. First, its descriptive na-
ture does not allow us to make firm mechanistic
inferences. Second, we did not study the expression of
LXA4 receptor (ALX/FPR2) which, according to recent
publications, may play an important role in the regula-
tion of catabasis [29,30]. Third, lung tissue samples were
obtained at surgery from patients suffering from cancer.
Despite that samples were always obtained from non-
affected distant areas from the tumour and that no
patient had received radio- or chemo-therapy before sur-
gery, we cannot exclude an influence of the tumour itself
on the results of our study. However, both COPD and
controls had cancer, so any eventual influence of the
tumour should have influence results in both groups.
Besides, this is a limitation of basically any study using
Noguera et al. Respiratory Research 2012, 13:101 Page 8 of 9
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relatively small sample size of our study and the fact
that, due to the origin of the tissue samples, we could
not study patients with more severe airflow limitation.
Conclusions
The results of this study support the hypothesis that cat-
abasis might be abnormal in COPD. If so, this may be a
key mechanism explaining the persistence of inflamma-
tion in these patients, even after quitting smoking, and,
potentially, the progression of the disease. The confirm-
ation of this hypothesis requires further research.
Additional file
Additional file 1: Table S1. Spearman Rho correlation matrix (A) and
corresponding p values (B) for all biomarkers determined in pulmonary
macrophages (M) and lung tissue extracts, as depicted graphically in
heat-map shown in Figure 4. For further explanations, see text. Table S2.
Z-scores of individual patients for each inflammatory marker determined
in pulmonary macrophages (M) and lung tissue extracts. For further
explanations, see text.
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